ST Pharm Co.,Ltd. (KOSDAQ:237690)
90,000
-1,800 (-1.96%)
Sep 11, 2026, 3:30 PM KST
ST Pharm Revenue
ST Pharm had revenue of 108.48B KRW in the quarter ending June 30, 2026, with 58.95% growth. This brings the company's revenue in the last twelve months to 386.46B, up 29.64% year-over-year. In the year 2025, ST Pharm had annual revenue of 331.68B with 21.16% growth.
Revenue (ttm)
386.46B
Revenue Growth
+29.64%
P/S Ratio
4.86
Revenue / Employee
590.01M
Employees
655
Market Cap
1.88T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 331.68B | 57.93B | 21.16% |
| Dec 31, 2024 | 273.75B | -11.24B | -3.94% |
| Dec 31, 2023 | 284.99B | 35.67B | 14.31% |
| Dec 31, 2022 | 249.32B | 83.68B | 50.52% |
| Dec 31, 2021 | 165.64B | 41.53B | 33.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| Sam Chun Dang Pharm. | 259.90B |
| BINEX | 157.28B |
| Oscotec | 144.18B |
| CG Invites | 30.11B |
| Mezzion Pharma | 8.43B |